Why the study?
Does a subxiphoid pericardial window improve survival in patients with malignant pericardial effusion from carcinoma of the bronchus compared to no pericardial window?
Does a subxiphoid pericardial window improve survival in patients with malignant pericardial effusion from carcinoma of the bronchus compared to no pericardial window?
A subxiphoid pericardial window is a safe and effective procedure for relieving cardiac compression in malignant pericardial effusion, though it does not significantly prolong overall survival, which likely depends on the primary tumor extent.
Answers are grounded in this paper and cite their sources.
Pericardial window shows no survival benefit in malignant effusion from lung cancer; leaves open its value for symptom relief in prospective studies.
The incidence of metastasis to the heart and pericardium was 35% in post-mortem studies of 150 cases of carcinoma of the bronchus. Twenty-one patients with malignant pericardial effusion from carcinoma of the bronchus were treated at the National Cancer Center Hospital during the last three years. Fifteen patients were treated by creating a pericardial window through a subxiphoid approach without complications or mortality, in these 15 patients cardiac compression caused by pericardial effusion was promptly relieved by the creation of the pericardial window. There was no reaccumula tion of the effusion in five of six patients treated by the pericardial window procedure with intrapericardial instillation of chemotherapeutic agents and eight of nine patients treated by creating the window without local chemotherapy. On the other hand cardiac tamponade was controlled in one of three patients by repeated pericardiocenteses. The median survival periods from the initiation of treatment for the effusion up to death were 4 mo in six patients treated by the pericardial window procedure with intrapericardial instillation of chemotherapeutic agents, 2 mo in nine patients treated by the window technique without local chemotherapy and 0.8 mo in six patients in whom a pericardial window was not created. The median survival of 15 patients treated by the pericardial window procedure (2 nio) was not significantly longer than that of six patients not so treated. We have come to the conclusion that the creation of a subxiphoid pericardial window is a safe, effective and reliable treatment procedure for the manage ment of malignant pericardial effusion, but the prognosis for survival in patients with malignant pericardial effusion may depend principally on the extent of the primary tumor and the performance status of patients at the initiation of treatment for the effusion.
No takes yet. Share an insight, caveat, or question.
Shinkai et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: